心脏骤停后目标温度管理:系统综述与贝叶斯Meta分析
该研究为系统综述与贝叶斯Meta分析,纳入7项随机或半随机对照试验共3792例心脏骤停后接受至少12小时目标温度管理的成人患者,比较32-34°C与无目标温度管理或组间温差>2°C。结果显示,32-34°C目标温度管理对死亡的RR为0.95(95%CrI 0.78-1.09),对不良神经结局的RR为0.93(95%CrI 0.84-1.02)。无获益的后验概率分别为24%和12%。排除4项对照组未主动控制发热的研究后,达到绝对风险降低>2%的概率降至≤50%。结论不支持32-34°C目标温度管理优于36°C并主动控制发热。
要点
- 32-34°C目标温度管理对死亡的RR为0.95(95%CrI 0.78-1.09),对不良神经结局的RR为0.93(95%CrI 0.84-1.02)。
- 无获益(RR≥1)的后验概率:死亡24%,不良神经结局12%。
- 32-34°C目标温度管理获益最可能对应绝对风险降低2-4%:死亡28-53%概率,不良神经结局63-78%概率。
- 排除4项对照组未主动控制发热的研究后,达到绝对风险降低>2%的概率降至≤50%。
- 低温目标温度管理的任何可能获益均小于既往随机对照试验所设定的目标。
适用人群与场景
- 成人心脏骤停后存活者,接受目标温度管理至少12小时。
处置流程与药物剂量
- 目标温度管理32-34°C与无目标温度管理或组间温差>2°C(对照)比较;排除4项对照组未主动控制发热的研究后,达到绝对风险降低>2%的概率降至≤50%。
研究设计与关键结果
- 研究设计:系统综述与贝叶斯Meta分析,纳入7项随机或半随机对照试验,共3792例患者,其中3项低偏倚风险、3项中等偏倚风险、1项高偏倚风险,证据确定性极低至低。
- 主要结局死亡:32-34°C目标温度管理的RR为0.95(95%CrI 0.78-1.09)。
- 次要结局不良神经恢复:32-34°C目标温度管理的RR为0.93(95%CrI 0.84-1.02)。
- 无获益(RR≥1)的后验概率:死亡24%,不良神经结局12%。
- 32-34°C目标温度管理获益最可能对应绝对风险降低2-4%:死亡28-53%概率,不良神经结局63-78%概率。
- 排除4项对照组未主动控制发热的研究后,达到绝对风险降低>2%的概率降至≤50%。
证据类型、等级与局限
- 证据类型:系统综述与贝叶斯Meta分析,纳入随机和半随机对照试验。
- 证据确定性:极低至低(采用GRADE方法评估)。
- 偏倚风险:3项低偏倚风险、3项中等偏倚风险、1项高偏倚风险。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,后验概率分布不支持使用32-34°C目标温度管理(相较于36°C并包括主动控制发热)来降低90-180天死亡和不良神经结局风险。
- 作者认为,低温目标温度管理的任何可能获益均小于既往随机对照试验所设定的目标。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Temperature control with target temperature management (TTM) after cardiac arrest has been endorsed by expert societies and adopted in international clinical practice guidelines but recent evidence challenges the use of hypothermic TTM.
METHODS: Systematic review and Bayesian meta-analysis of clinical trials on adult survivors from cardiac arrest undergoing TTM for at least 12 h comparing TTM versus no TTM or with a separation > 2 °C between intervention and control groups using the PubMed/MEDLINE, EMBASE, CENTRAL databases from inception to 1 September 2021 (PROSPERO CRD42021248140). All randomised and quasi-randomised controlled trials were considered. The risk ratio and 95% confidence interval for death (primary outcome) and unfavourable neurological recovery (secondary outcome) were captured using the original study definitions censored up to 180 days after cardiac arrest. Bias was assessed using the updated Cochrane risk-of-bias for randomised trials tool and certainty of evidence assessed using the Grading of Recommendation Assessment, Development and Evaluation methodology. A hierarchical robust Bayesian model-averaged meta-analysis was performed using both minimally informative and data-driven priors and reported by mean risk ratio (RR) and its 95% credible interval (95% CrI).
RESULTS: In seven studies (three low bias, three intermediate bias, one high bias, very low to low certainty) recruiting 3792 patients the RR by TTM 32-34 °C was 0.95 [95% CrI 0.78-1.09] for death and RR 0.93 [95% CrI 0.84-1.02] for unfavourable neurological outcome. The posterior probability for no benefit (RR ≥ 1) by TTM 32-34 °C was 24% for death and 12% for unfavourable neurological outcome. The posterior probabilities for favourable treatment effects of TTM 32-34 °C were the highest for an absolute risk reduction of 2-4% for death (28-53% chance) and unfavourable neurological outcome (63-78% chance). Excluding four studies without active avoidance of fever in the control arm reduced the probability to achieve an absolute risk reduction > 2% for death or unfavourable neurological outcome to ≤ 50%.
CONCLUSIONS: The posterior probability distributions did not support the use of TTM at 32-34 °C compared to 36 °C also including active control of fever to reduce the risk of death and unfavourable neurological outcome at 90-180 days. Any likely benefit of hypothermic TTM is smaller than targeted in RCTs to date.
参考来源
- Aneman A, Frost S, Parr M, et al. Target temperature management following cardiac arrest: a systematic review and Bayesian meta-analysis. Crit Care. 2022. PMID: 35279209. doi:10.1186/s13054-022-03935-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。